Caladrius Biosciences, Inc. (CLBS) News Headlines

▮ More

Date

Headline

9/14/2022 11:03:21 AM Caladrius Biosciences Tanks 19% On Proposed Merger

9/14/2022 8:30:59 AM Caladrius Biosciences Announces Approval Of Merger And Name Change To Lisata Therapeutics

8/2/2022 8:47:25 AM Caladrius Biosciences Completes Enrollment In Phase 1b Study Of CLBS201 For Diabetic Kidney Disease

5/19/2022 8:15:14 AM Caladrius Biosciences Announces IDMC Recommendation To Advance CLBS201 Trial For Diabetic Kidney Disease

3/23/2022 4:52:06 AM BNR's Revenue To Grow 22% In 2022; CINC To Report BrigHtn Data In 2H, SCPH To Resubmit NDA On Apr.15

3/8/2021 8:12:08 AM Caladrius Biosciences Reports Orphan Drug Designation For CLBS12 For Treatment Of Buerger’s Disease

1/21/2021 5:46:40 AM Pre-market Movers In Healthcare Sector: ADXN, CLSN, CLBS, JAGX, ECOR, ADMP…

1/21/2021 12:48:03 AM PFE/BNTX Covid Jab Neutralizes UK Strain, Pura Vida Ups Stake In OCX, Woodcock Is Interim FDA Chief

1/20/2021 10:16:38 AM Stock Alert: Caladrius Biosciences Hits New High

5/14/2019 6:43:19 AM WBB Securities Starts Caladrius Biosciences, Inc. (CLBS) At Speculative Buy With $6.75 Price Target

Older Articles